Publication|Videos|October 3, 2024
FSP Partnership: A Foundation for Innovation and Patient-Guided Development
Author(s)PAREXEL
Liz Rogers, VP and Head of Global Site and Study Operations at Pfizer, discusses Pfizer's partnership with Parexel and transition to a functional service provider (FSP) model.
- Transitioning to an FSP model, strategically allocating resources, and leveraging partnerships introduced a more streamlined and efficient model, enhancing resource efficiency and flexibility. The approach has enabled the sponsor (Pfizer) to tap into specialized expertise while maintaining control and oversight of clinical operations.
- Growing core capabilities in site and study management further enhanced site performance and oversight of quality and compliance. Further strengthening relationships with sites is key to the strategy alongside supporting novel recruitment models, shifting to remote monitoring, and focusing on fewer, higher-performing clinical sites.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
2
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
3
FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results
4
ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
